Editas Medicine
EDIT
305 hedge funds and large institutions have $1.35B invested in Editas Medicine in 2021 Q4 according to their latest regulatory filings, with 54 funds opening new positions, 84 increasing their positions, 91 reducing their positions, and 66 closing their positions.
8% less repeat investments, than reductions
Existing positions increased: 84 | Existing positions reduced: 91
2.26% less ownership
Funds ownership: 76.73% → 74.48% (-2.3%)
4% less funds holding
Funds holding: 318 → 305 (-13)
18% less first-time investments, than exits
New positions opened: 54 | Existing positions closed: 66
38% less capital invested
Capital invested by funds: $2.17B → $1.35B (-$814M)
53% less call options, than puts
Call options by funds: $23.8M | Put options by funds: $50.7M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
State Street
Boston,
Massachusetts
|
+$38.4M |
| 2 |
Millennium Management
New York
|
+$33.6M |
| 3 |
Two Sigma Investments
New York
|
+$20.1M |
| 4 |
Marshall Wace
London,
United Kingdom
|
+$13.3M |
| 5 |
Two Sigma Advisers
New York
|
+$11.9M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AIM
ARK Investment Management
St. Petersburg,
Florida
|
-$71.6M |
| 2 |
NAMA
Nikko Asset Management Americas
New York
|
-$54.6M |
| 3 |
Sumitomo Mitsui Trust Group
Minato-Ku, Tokyo,
Japan
|
-$54.6M |
| 4 |
Lord, Abbett & Co
Jersey City,
New Jersey
|
-$29.1M |
| 5 |
Goldman Sachs
New York
|
-$13.8M |
EDIT Hedge Fund Activity: Q4 2021 in Review
305 of the 6,498 institutional investors tracked by Wall St. Rank reported a position in Editas Medicine (EDIT) for Q4 2021, worth a combined $1.35B — down 38% from $2.17B a quarter earlier.
Sellers outnumbered buyers: 66 funds closed out of EDIT and 54 opened new positions — a net loss of 12 holders — while 91 trimmed existing stakes and 84 added.
The largest buyer was State Street, adding an estimated $38.4M. The largest seller was ARK Investment Management, cutting an estimated $71.6M.
- 305 institutional investors held Editas Medicine (EDIT) as of Q4 2021, down from 318 in Q3 2021.
- Funds reported $1.35B of Editas Medicine stock for Q4 2021, down 38% quarter-over-quarter.
- 54 funds opened new Editas Medicine positions in Q4 2021 and 66 closed out, a net change of -12 holders.
- The largest Editas Medicine buyer in Q4 2021 was State Street, an estimated $38.4M added.
- The largest Editas Medicine seller in Q4 2021 was ARK Investment Management, an estimated $71.6M sold.
Based on aggregated 13F filings for Q4 2021.